Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
RMIT Heart Patch Aims for 18x Cleaner ECG Data in Clinical Trial

RMIT Heart Patch Aims for 18x Cleaner ECG Data in Clinical Trial

November 20, 2026 Health Desk Health

A flexible, gel-free wireless ECG patch, developed by Lubdub and RMIT University, is undergoing clinical trials designed to replace traditional Holter monitors by delivering heart rhythm data 18 times cleaner.

The patch allows continuous cardiac monitoring for up to 14 days, advancing non-invasive cardiovascular screening.

Key Clinical Takeaways:

  • The wireless patch provides an 18-fold increase in signal clarity compared to standard Holter monitors during preliminary testing.
  • The technology is being trialed in Perth, Western Australia, aiming to improve cardiac monitoring access in both metropolitan and remote regions.
  • Lubdub plans to integrate ECG, non-invasive cardiac biomarker testing, and wearable ultrasound imaging into a single diagnostic platform.

Cardiovascular disease remains a major global health burden, responsible for a third of all deaths worldwide and nearly a quarter of fatalities in Australia. The challenge lies in the fact that early symptoms of heart conditions are frequently missed.

According to Lubdub, the majority of heart failure diagnoses and hospital admissions are unplanned, occurring during emergency situations despite patients often experiencing symptoms for years prior. This clinical gap necessitates more effective preventative screening.

Mechanism of Enhanced Signal Acquisition

The core innovation of the patch lies in its flexible sensor design, which allows for superior contact with the skin compared to the rigid sensors used in traditional Holter monitors. RMIT Professor and Lubdub co-founder Sharath Sriram explained that this design choice improves data quality. Sriram stated, “The flexible sensors make better contact with the skin than those used in traditional Holter monitors.”

This improved physical contact translates into a cleaner data stream, which the company reported was 18 times clearer than conventional monitoring methods in initial testing with healthy volunteers. This enhanced signal integrity allows clinicians to capture subtle arrhythmias and cardiac events that might otherwise be missed by standard monitoring approaches.

The Lubdub prototype ECG patch is currently being used as part of a clinical trial at Midlands Medical Specialists in Perth, Western Australia. Patients prescribed a Holter monitor will wear the new device, which aims to provide the detailed diagnostic information of a medical-grade electrocardiogram (ECG).

The technology is designed not just for hospital settings but for continuous use during the patient’s daily activities, making high-quality heart rhythm assessment more accessible outside of clinical environments.

The development of this technology holds substantial promise for clinical efficiency. Sharath Sriram said that by streamlining the process of generating complex cardiac reports, the same healthcare workforce could potentially monitor up to 85% more patients before the implementation of advanced enabling tools like Artificial Intelligence. The Heart Foundation has recognized the potential of this innovation, selecting Lubdub as one of its ten most promising heart health projects for 2026.

Expanding Heart Health Access Globally

Lubdub’s mission transcends technological innovation; it addresses critical gaps in global healthcare infrastructure. Co-Founder and Director Nikhilesh Bappoo articulated that the goal is to make heart testing more accessible, particularly in areas where cost, limited infrastructure, specialist shortages, and long waiting periods often delay diagnosis. Bappoo’s determination was informed by his family’s healthcare experiences, prompting him to reflect on the differences between receiving timely specialist care in Australia and the limited access available in his home country of Mauritius.

This focus on accessibility is central to the company’s vision of “Heart health in a box.”

“Had it happened there, the outcome could have been very different,” Co-Founder and Director Nikhilesh Bappoo said.

The platform ultimately seeks to integrate three distinct diagnostic modalities: wearable ECG monitoring, non-invasive cardiac biomarker testing, and wearable ultrasound imaging. This integrated approach addresses the current fragmented nature of cardiac diagnostics, where a patient may require separate appointments, specialists, and facilities for an ECG, blood tests, or an echocardiogram, depending on their symptomatic presentation.

Lubdub Secures $6 Million Seed Funding for Regulatory Approval

The commercialization of this research has been supported by substantial private investment. In September, Lubdub announced it had secured an oversubscribed $6 million seed funding round. This figure doubled the original $3 million funding target, demonstrating strong confidence from investors, many of whom are physicians and heart specialists. This capital allows the company to advance the technology toward necessary regulatory approval.

The research itself originated from RMIT University, which licensed the intellectual property for the ECG and biomarker inventions to Lubdub. RMIT’s Deputy Vice-Chancellor Research and Innovation, Distinguished Professor Calum Drummond AO, confirmed that the licensing agreement exemplifies how university research can be translated into practical benefits. Drummond said that Lubdub is focused on improving heart health through cutting-edge electronics invented at RMIT.

Long-term Trajectory of Wearable Cardiology

The clinical trial currently underway will gather the necessary evidence to support the technology’s further development and eventual regulatory approval. Proponents of the patch highlight its potential to reduce the time interval between cardiovascular symptoms and definitive treatment.

According to Sharath Sriram, the innovation is focused on simpler and more effective screening, resting on the principle that prevention is superior to cure. The technology, the first of three planned by Lubdub, moves toward transforming how chronic and acute cardiac conditions are managed outside traditional clinical settings.

The current clinical testing at Midlands Medical Specialists provides vital data on the real-world efficacy and user comfort of the prototype. This data will inform the refinement of the platform as it moves toward broader market viability. Lubdub, in partnership with RMIT, will continue to refine the technology as it works toward clinical standardization.

RMIT University, the research partner behind the patch, traces its origins to 1887, when it opened in Melbourne as the Working Men’s College, a night school offering instruction in art, science and technology.

It became the first Australian tertiary education provider to be awarded royal patronage, in 1954, and remains the only Australian higher education institution entitled to the “Royal” prefix. Now a public research university with an enrolment of around 95,000 students, it is ranked 15th in the world for art and design subjects in the QS World University Rankings.


Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Worth a look

  • Federal Judge Extends Block on Trump Arch Construction
  • Logistics Reply Implements Robot-Assisted Intralogistics System at The Quality Group New Fulfilment Centre
  • RMIT-Invented Waterproof Wireless ECG Patch Enters Clinical Trial (archyde.com)

Related

Biomarker, Clinical Trial, heart, imaging, research, technology, ultrasound

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service